BridgeBio Pharma, Inc. beat EPS estimates 25% of the time across 16 reported quarters (4 beats, 12 misses), averaging -7.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.64 | $-0.78 | -21.9% | Miss | |
| Q1 FY26 | $-0.70 | $-0.84 | -20.0% | Miss | Q1 FY26 call |
| Q4 FY25 | not reported | $1.00 | not reported | not reported | Q4 FY25 call |
| Q3 FY25 | $-0.88 | $-0.95 | -8.0% | Miss | |
| Q2 FY25 | $-0.83 | $-0.95 | -14.5% | Miss | |
| Q1 FY25 | not reported | $-0.88 | not reported | not reported | |
| Q4 FY24 | $-1.09 | $-1.31 | -20.2% | Miss | |
| Q3 FY24 | $-1.03 | $-0.86 | +16.5% | Beat | |
| Q2 FY24 | $-1.09 | $-1.02 | +6.4% | Beat | |
| Q1 FY24 | not reported | $-0.05 | not reported | not reported | |
| Q4 FY23 | $-0.95 | $-0.96 | -1.1% | Miss | |
| Q3 FY23 | $-0.86 | $-1.08 | -25.6% | Miss |
Back to BBIO overview · BBIO holders · BBIO KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.